SUBPART A—Specific Sector Provisions for Pharmaceutical Good Manufacturing Practices (§26.1 to §26.21)
- 26.1—Definitions.
- 26.2—Purpose.
- 26.3—Scope.
- 26.4—Product coverage.
- 26.5—Length of transition period.
- 26.6—Equivalence assessment.
- 26.7—Participation in the equivalence assessment and determination.
- 26.8—Other transition activities.
- 26.9—Equivalence determination.
- 26.10—Regulatory authorities not listed as currently equivalent.
- 26.11—Start of operational period.
- 26.12—Nature of recognition of inspection reports.
- 26.13—Transmission of postapproval inspection reports.
- 26.14—Transmission of preapproval inspection reports.
- 26.15—Monitoring continued equivalence.
- 26.16—Suspension.
- 26.17—Role and composition of the Joint Sectoral Committee.
- 26.18—Regulatory collaboration.
- 26.19—Information relating to quality aspects.
- 26.20—Alert system.
- 26.21—Safeguard clause.